Exeltis USA v. Glenmark: Contraceptive Patent Suit Dismissed With Prejudice
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Exeltis USA, Inc. v. Glenmark Pharmaceuticals |
| Case Number | 2:25-cv-17250 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Nov 2025 – Mar 2026 4 months |
| Outcome | Dismissed With Prejudice (No Damages Disclosed) |
| Patents at Issue | |
| Accused Products | Glenmark’s drospirenone formulations and pharmaceutical compositions |
Case Overview
The Parties
⚖️ Plaintiff
U.S. commercial arm of a global specialty pharmaceutical company, marketing SLYND® (drospirenone) as a progestin-only oral contraceptive.
🛡️ Defendant
Multinational generic and specialty drug manufacturer with significant U.S. market operations, seeking to introduce lower-cost alternatives.
Patents at Issue
This dispute involved an expansive portfolio of **18 U.S. patents** protecting the branded contraceptive SLYND® (drospirenone) and related pharmaceutical compositions and delivery methods. These patents collectively cover drospirenone-based pharmaceutical compositions, contraceptive kit configurations, and methods of administering synthetic progestogens, forming a dense defensive perimeter around the SLYND® product franchise.
- • US10849857B2, US11951213B2, US11123299B2, US10179140B2, US9603860B2
- • US11439598B2, US10603281B2, US12280151B2, US11291633B2, US10987364B1
- • US11413249B2, US11291632B2, US11491113B1, US11351122B1, US11452695B2
- • US11478487B1, US11504334B2, US12090231B2
Developing a similar pharmaceutical product?
Check if your drospirenone formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was resolved by stipulated dismissal with prejudice as to all claims and defenses asserted by both parties. The dismissal order explicitly provides that no costs or attorneys’ fees were awarded to any party. No damages figure was publicly disclosed, and no injunctive relief was ordered as part of the public record.
Key Legal Issues
The rapid resolution—without any substantive motions or claim construction proceedings concluding—suggests that **settlement leverage was asymmetric early**. With 18 patents asserted, Glenmark faced substantial litigation exposure and cost. The breadth of Exeltis’s portfolio likely accelerated settlement incentives. This case reinforces the strategic value of **layered patent portfolios** that protect a single drug franchise through overlapping claim scopes across composition, method-of-use, and formulation patents.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in contraceptive drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 18 asserted patents in this technology space
- See which companies are most active in contraceptive patents
- Understand claim construction patterns for drospirenone
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Drospirenone-based pharmaceutical compositions
18 Asserted Patents
Covering SLYND® franchise
Design-Around Options
Feasible, but complex due to layered claims
✅ Key Takeaways
Asserting a broad continuation patent portfolio (18 patents) creates compounding litigation exposure that accelerates defendant settlement behavior.
Search related case law →Stipulated dismissals with prejudice in pharma cases typically signal confidential licensing resolutions, not outright concessions.
Explore precedents →New Jersey remains a strategically preferred forum for branded pharmaceutical patent enforcement.
Explore court analytics →Frequently Asked Questions
The case involved 18 U.S. patents covering drospirenone (SLYND®) compositions, synthetic progestogen formulations, contraceptive kits, and related methods of administration, including US10849857B2, US11951213B2, and US12280151B2, among others.
The parties filed a joint stipulation of dismissal with prejudice, with no costs or attorneys’ fees awarded. The public record contains no judicial rulings on infringement or validity, strongly suggesting a private settlement or licensing agreement.
It reinforces that broad, layered pharmaceutical patent portfolios—covering a single drug across multiple claim types—create significant litigation leverage, often producing early resolution before substantive merits proceedings.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup – Case No. 2:25-cv-17250
- USPTO Patent Full-Text Database for US10849857B2 and related patents
- U.S. Patent and Trademark Office — Patent Resources
- World Intellectual Property Organization — Pharmaceutical Patents
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.